This study is an open label Phase II study aimed to recruit at least 20 patients with inoperable PDA and who are positive for CA19.9 pancreatic tumor marker. The presence of higher than normal levels of CA19.9 is the sole inclusion criteria. Patients will be given one tablet of V3-P daily and followed for three months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
diagnosis of inoperable pancreatic cancer
higher than normal of serum CA19.9 tumor marker levels (40 IU/ml)
